BioXcel Therapeutics Inc (BTAI) — Cash Flow-to-Debt Ratio
BioXcel Therapeutics Inc (BTAI) has a Cash Flow-to-Debt Ratio of -0.10x as of December 2025, meaning its operating cash flow of $-14.21 Million could theoretically repay 0% of its total liabilities ($140.38 Million) in one year. See BioXcel Therapeutics Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
BioXcel Therapeutics Inc Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for BioXcel Therapeutics Inc across 11 annual periods. Also explore BTAI shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for BioXcel Therapeutics Inc (2015–2025)
Year-by-year debt coverage analysis for BioXcel Therapeutics Inc. For market capitalisation and broader financial context, see market value of BioXcel Therapeutics Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.41x | $-57.62 Million | $140.38 Million | ▲ +25.1% |
| 2024 | -0.55x | $-72.03 Million | $131.44 Million | ▲ +54.0% |
| 2023 | -1.19x | $-155.01 Million | $130.21 Million | ▼ -13.5% |
| 2022 | -1.05x | $-135.34 Million | $129.08 Million | ▲ +77.3% |
| 2021 | -4.62x | $-82.15 Million | $17.77 Million | ▲ +7.8% |
| 2020 | -5.01x | $-66.35 Million | $13.24 Million | ▼ -74.5% |
| 2019 | -2.87x | $-27.28 Million | $9.50 Million | ▲ +0.9% |
| 2018 | -2.90x | $-13.51 Million | $4.66 Million | ▼ -208.5% |
| 2017 | -0.94x | $-2.20 Million | $2.34 Million | ▲ +76.0% |
| 2016 | -3.91x | $-1.29 Million | $331.00K | ▼ -144.3% |
| 2015 | -1.60x | $-280.00K | $175.00K | — |